Výsledky vyhledávání - "D. Ponce de Leon"

Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs

Autor: MV Gutierrez-Ardila, Jm Reyes, H Madariaga, W Otero, R Guzman, J Izquierdo, M Abello, P Velez, D Castillo, D Ponce de Leon, T Lukic, L Amador

Publikováno v: Expert Review of Pharmacoeconomics & Outcomes Research. 22:787-794

To evaluate work productivity of adult Latin American patients with rheumatoid arthritis (RA) treated with tofacitinib and biological disease-modifying anti-rheumatic drugs (bDMARDs) measured by the Work Productivity and Activity Impairment (WPAI) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503fd2333fa81ed24415d372b29a6074
https://doi.org/10.1080/14737167.2022.2047935

Zobrazit plný text záznamu

P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis

Autor: Simon Travis, D. Ponce de Leon, Chinyu Su, Michael Chiorean, Iris Dotan, E Maller, Irene Modesto, Jerome Paulissen, Silvio Danese, J.-F. Colombel, Jesús K. Yamamoto-Furusho

Publikováno v: Journal of Crohn's and Colitis. 14:S321-S323

Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Safety and efficacy of tofacitinib in patients with UC were evaluated in two Phase 3 induction studies (OCTAVE Induction 1 and 2; NCT0146576

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d8bda447136ee273efefb1c7c17ca96
https://doi.org/10.1093/ecco-jcc/jjz203.463

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0831 COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES

Autor: Rajiv Mundayat, Josef S Smolen, Enrique R. Soriano, Daniela Graham, Annette Szumski, D. Ponce de Leon, Gustavo Citera, P. Nash, Emilce Edith Schneeberger, P. J. Mease, Claudia Helling

Publikováno v: Annals of the Rheumatic Diseases. 79:1720-1721

Background:An international task force has agreed that remission and low disease activity (LDA) are treatment targets for patients (pts) with PsA, and recommends the Disease Activity Index in Psoriatic Arthritis (DAPSA) and minimal disease activity (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f3e386986d3de78577a2e7d5c9832ac
https://doi.org/10.1136/annrheumdis-2020-eular.948

Zobrazit plný text záznamu

THU0196 TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INDICATIVE OF DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 CLINICAL TRIALS

Autor: D. Ponce de Leon, A. Ebrahim, Lori Stockert, F. Irazoque-Palazuelos, Lisy Wang, Ming-Ann Hsu, K. Santana, H. Madariaga, David Gruben, Gustavo Citera, R. Jain, R. Guzman

Publikováno v: Annals of the Rheumatic Diseases. 79:318-319

Background:Depression/anxiety are common in RA pts. SF-36 MCS ≤38 can identify probable major depressive disorder and/or probable generalised anxiety disorder (pMDD/pGAD) in RA pts. Tofacitinib is an oral JAK inhibitor for the treatment of RA.Objec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c501aa9c36bcbb503204567ebfd9271
https://doi.org/10.1136/annrheumdis-2020-eular.417

Zobrazit plný text záznamu

P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies

Autor: Nicole Kulisek, J.-F. Colombel, D. Ponce de Leon, Joseph C. Cappelleri, Andrew G. Bushmakin, Genoile O. Santana, Peter L. Lakatos, Nervin Lawendy

Publikováno v: Journal of Crohn's and Colitis. 14:S328-S329

Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In patients with UC, associations between endoscopic findings and patient-reported outcomes, such as stool frequency (SF) and rectal bleedin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d1c22b4b715ca1db96e24ce0da2659a7
https://doi.org/10.1093/ecco-jcc/jjz203.471

Zobrazit plný text záznamu

P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2

Autor: Nicole Kulisek, D. Ponce de Leon, David Hudesman, Leonardo Salese, Chinyu Su, Marla Dubinsky, Flavio Steinwurz, Fernando Magro, Jerome Paulissen

Publikováno v: Journal of Crohn's and Colitis. 14:S346-S347

Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In a Phase 2 study, changes from baseline in C-reactive protein (CRP) levels as early as Week 4 and partial Mayo scores (PMS) as early as We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35fc394d3cf4041276003446e71bb001
https://doi.org/10.1093/ecco-jcc/jjz203.495

Zobrazit plný text záznamu

FRI0099 Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes

Autor: Enrique R. Soriano, D. Ponce de Leon, Emilce Edith Schneeberger, Harry Shi, Gustavo Citera, Mario H. Cardiel, H. Madariaga, Daniela Graham, Thijs Hendrikx, Oswaldo Castañeda

Publikováno v: FRIDAY, 15 JUNE 2018.

Background Non-alcoholic fatty liver disease, characterised by hepatic steatosis (HS), is a major cause of chronic liver disease in many countries. Limited data are available on liver enzyme elevation in patients (pts) with HS who are receiving medic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45dbf6490e0e39ec40aa0b35252e4266
https://doi.org/10.1136/annrheumdis-2018-eular.2517

Zobrazit plný text záznamu

AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference

Autor: N. Betteridge, Lara Fallon, David Gruben, Diane Whalley, C. Zerbini, Alan J Kivitz, John Woolcott, T.M. Brown, Connie Chen, D. Ponce de Leon, Oyebimpe Olayinka-Amao, Peter C. Taylor, P. Dahl

Publikováno v: Rheumatoid arthritis – prognosis, predictors and outcome.

Background Little in-depth qualitative research has been conducted to investigate reasons for rheumatoid arthritis (RA) patient (pt) preferences for different modes of treatment administration. An understanding of pt preference can help physicians pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::149b82b311b4b395d79cee3bed6044e0
https://doi.org/10.1136/annrheumdis-2018-eular.2039

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání